Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients - Quiz - MDSpire

Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients

  • By

  • Huan Xie

  • Maoyuan Xiang

  • Meijuan Zhang

  • Fanqiao Meng

  • Yan Qi

  • Kehong Chen

  • Dongfeng Zeng

  • June 23, 2026

  • 0 min

Share

Original Source(s)

Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients

  • by Huan Xie, Maoyuan Xiang, Meijuan Zhang, Fanqiao Meng, Yan Qi, Kehong Chen, Dongfeng Zeng

  • June 23, 2026

Related Content

cfDNA’s Big Moment Has Arrived

Experts explore the promise, pitfalls, and future of cfDNA testing in modern laboratory medicine

Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies

Association between radiotherapy timing and intracranial outcomes in EGFR-mutant NSCLC with brain metastases treated with EGFR-TKIs